JBIO — Jade Biosciences, Inc. stock price, charts and financials

QT86Jade Biosciences, Inc.

Jade Biosciences, Inc. (NASDAQ: JBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
21.35
+2.20+11.49%
OverviewShort InterestFilings
JBIOQT86Jade Biosciences, Inc.·NASDAQ
21.35+11.49%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E-EPS (ttm)-Insider Own15.10%Shs Outstand32.63MPerf Week8.38%
Market Cap696.56MForward P/E-EPS next Y-2.61Insider Trans0.00%Shs Float24.29MPerf Month0.23%
Enterprise Value386.56MPEG-EPS next Q-Inst Own-Short Float31.00%Perf Quarter-12.93%
Income-127.00MP/S0.00EPS this Y-Inst Trans-Short Ratio7.30Perf Half Y28.23%
Sales0.00P/B2.35EPS next Y0.49%ROA-40.57%Short Interest7.53MPerf YTD38.37%
Book/sh9.07P/C2.24EPS next 5Y-ROE-51.34%52W High28.00 -23.75%Perf Year209.87%
Cash/sh9.53P/FCF-EPS past 3/5Y-ROIC-44.96%52W Low6.67 220.09%Perf 3Y-96.50%
Dividend Est.2.40 (11.24%)EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.47% 7.75%Perf 5Y-95.23%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM97.63%Oper. Margin0.00%ATR (14)1.60Perf 10Y-
Dividend Ex-DateApr 29, 2025Quick Ratio14.29Sales Y/Y TTM-Profit Margin0.00%RSI (14)56.16Recom2.00
Dividend Gr. 3/5Y-Current Ratio14.29EPS Q/Q-533.33%SMA203.94%Beta1.40Target Price44.33
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA508.11%Rel Volume1.60Prev Close19.15
Employees55LT Debt/Eq0.00EarningsAug 12SMA20028.43%Avg Volume1.05MPrice21.35
IPO DateJun 30, 2021Option/ShortYes / YesEPS/Sales Surpr.-18.12% -Net Debt/EBITDA0.42Volume1,687,327Change11.49%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26InitiatedUBSBuy$45
Jun-02-26ReiteratedPiper Sandler$55
Jun-02-26ReiteratedGuggenheimBuy$32 → $47
May-11-26ReiteratedWedbushOutperform$34
May-11-26ReiteratedGuggenheimBuy$14 → $32
Apr-27-26ReiteratedHC Wainwright & Co.Buy$25 → $45
Mar-06-26ReiteratedStifel Nicolaus$19 → $40
Jan-07-26InitiatedH.CBuy$25
Oct-09-25InitiatedBTIGBuy$28
Jun-16-25UpgradeGuggenheimNeutral → Buy$14
Latest News
Company

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000000
Cost of Goods Sold Incl. D&A
000000
Gross Profit
000000
Selling, General and Administrative Excl. Other2021171581
Research and Development93536439158
Other Operating Expense100-100
Operating Income-114-75-81-53-23-9
Interest Expense
000000
Unusual Expense
——————
Non-Operating Income (Expense)-145620-1
Net Income Before Taxes-127-70-75-51-23-10
Income Taxes
000000
Consolidated Net Income-127-70-76-52-23-10
Net Income From Continuing Operations-127-70-76-52-23-10
Net Income-127-70-76-52-23-10
EPS (Recurring)-4.06-85.26-100.38-73.67-32.96-14.00
EPS (Basic, Before Extraordinaries)-4.06-85.26-100.38-73.67-32.96-14.00
EPS (Diluted)-4.06-85.26-100.38-73.67-32.96-14.00
EBITDA-127-69-75-51-23-10
Other After Tax Adjustments
——————
Stock Option Compensation Expense
——————
Price To Earnings Ratio
——————
Price To Sales Ratio
——————
Gross Margin
——————
Operating Margin
——————
Net Margin
——————
Shares Outstanding3111111
Market Capitalization478937921,026413—
Operating Lease Expense
——————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.86$23.33$16.80$10.28$3.75● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Frohlich TomChief Executive OfficerMay 16 '25Buy7.406,00044,4006,000May 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.